14 maart 2022: Bron: The Lancet  VOLUME 23, ISSUE 3P416-427, MARCH 01, 2022

Toevoeging van isatuximab aan de medicijnencombinatie pomalidomide plus dexamethason bij patiënten met de ziekte van Kahler - multiple myeloma (botkanker) geeft mediaan een verschil van 6,9 maanden in de mediane totale overleving vergeleken met alleen pomalidomide plus dexamethason. Dat blijkt uit de followup resultaten van de fase III studie ICARIA-MM .

Volgens de onderzoekers wordt deze combinatie een nieuwe standaardbehandeling voor lenalidomide resistente en proteasoomremmer resistente of recidiverend multiple myeloma - ziekte van Kahler / botkanker.

Het volledige studierapport is tegen betaling in te zien. Hier het abstract zoals gepubliceeerd in The Lancet:

ARTICLES| VOLUME 23, ISSUE 3P416-427, MARCH 01, 2022

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study



The primary analysis of the ICARIA-MM study showed significant improvement in progression-free survival with addition of isatuximab to pomalidomide–dexamethasone in relapsed and refractory multiple myeloma. Here, we report a prespecified updated overall survival analysis at 24 months after the primary analysis.


In this randomised, multicentre, open-label, phase 3 study adult patients (aged ≥18 years) with relapsed and refractory multiple myeloma who had received at least two previous lines of therapy, including lenalidomide and a proteasome inhibitor, and had an Eastern Cooperative Oncology Group performance status of 0–2 were recruited from 102 hospitals in 24 countries across Europe, North America, and the Asia-Pacific regions. Patients were excluded if they had anti-CD38 refractory disease or previously received pomalidomide. Patients were randomly assigned (1:1), using an interactive response technology with permuted blocked randomisation (block size of four) and stratified by number of previous treatment lines (2–3 vs >3) and aged (<75 vs ≥75 years), to isatuximab–pomalidomide–dexamethasone (isatuximab group) or pomalidomide–dexamethasone (control group). In the isatuximab group, intravenous isatuximab 10 mg/kg was administered on days 1, 8, 15, and 22 of the first 4-week cycle, and then on days 1 and 15 of subsequent cycles. Both groups received oral pomalidomide 4 mg on days 1–21 of each cycle, and weekly oral or intravenous dexamethasone 40 mg (20 mg if aged ≥75 years) on days 1, 8, 15, and 22 of each cycle. Treatment was continued until disease progression, unacceptable toxicity, or withdrawal of consent. Here' we report a prespecified second interim analysis of overall survival (time from randomisation to any-cause death), a key secondary endpoint, in the intention-to-treat population (ie, all patients who provided informed consent and allocated a randomisation number) at 24 months after the primary analysis. Safety was assessed in all patients who received at least one dose or part dose of study treatment. The prespecified stopping boundary for the overall survival analysis was when the derived p value was equal to or less than 0·0181. This study is registered with ClinicalTrials.govNCT02990338, and is active, but not recruiting.


Between Jan 10, 2017, and Feb 2, 2018, 387 patients were screened and 307 randomly assigned to either the isatuximab (n=154) or control group (n=153). Median follow-up at data cutoff (Oct 1, 2020) was 35·3 months (IQR 33·5–37·4). Median overall survival was 24·6 months (95% CI 20·3–31·3) in the isatuximab group and 17·7 months (14·4–26·2) in the control group (hazard ratio 0·76 [95% CI 0·57–1·01]; one-sided log-rank p=0·028, not crossing prespecified stopping boundary). The most common grade 3 or worse treatment-emergent adverse events in the isatuximab group versus the control group were neutropenia (76 [50%] of 152 patients vs 52 [35%] of 149 patients), pneumonia (35 [23%] vs 31 [21%]), and thrombocytopenia (20 [13%] vs 18 [12%]). Serious treatment-emergent adverse events were observed in 111 (73%) patients in the isatuximab group and 90 (60%) patients in the control group. Two (1%) treatment-related deaths occurred in the isatuximab group (one due to sepsis and one due to cerebellar infarction) and two (1%) occurred in the control group (one due to pneumonia and one due to urinary tract infection).


Addition of isatuximab plus pomalidomide–dexamethasone resulted in a 6·9-month difference in median overall survival compared with pomalidomide–dexamethasone and is a new standard of care for lenalidomide-refractory and proteasome inhibitor-refractory or relapsed multiple myeloma. Final overall survival analysis follow-up is ongoing.




  1. 1.
    • Moreau P 
    • Zamagni E 
    • Mateos MV
    Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide.
    Blood Cancer J. 2019; 938
  2. 2.
    • Kumar SK 
    • Lee JH 
    • Lahuerta JJ 
    • et al.
    Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.
    Leukemia. 2012; 26149-157
  3. 3.
    • van de Donk NWCJ 
    • Richardson PG 
    • Malavasi F
    CD38 antibodies in multiple myeloma: back to the future.
    Blood. 2018; 13113-29
  4. 4.
    • Munshi C 
    • Aarhus R 
    • Graeff R 
    • Walseth TF 
    • Levitt D 
    • Lee HC
    Identification of the enzymatic active site of CD38 by site-directed mutagenesis.
    J Biol Chem. 2000; 27521566-21571
  5. 5.
    • Malavasi F 
    • Deaglio S 
    • Funaro A 
    • et al.
    Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology.
    Physiol Rev. 2008; 88841-886
  6. 6.
    • Chillemi A 
    • Quarona V 
    • Antonioli L 
    • Ferrari D 
    • Horenstein AL 
    • Malavasi F
    Roles and modalities of ectonucleotidases in remodeling the multiple myeloma niche.
    Front Immunol. 2017; 8305
  7. 7.
    • Martin TG 
    • Corzo K 
    • Chiron M 
    • et al.
    Therapeutic opportunities with pharmacological inhibition of CD38 with isatuximab.
    Cells. 2019; 81522
  8. 8.
    • Horenstein AL 
    • Faini AC 
    • Morandi F 
    • et al.
    The circular life of human CD38: from basic science to clinics and back.
    Molecules. 2020; 254844
  9. 9.
    • Zhu C 
    • Song Z 
    • Wang A 
    • et al.
    Isatuximab acts through Fc-dependent, independent, and direct pathways to kill multiple myeloma cells.
    Front Immunol. 2020; 111771
  10. 10.
    • Jiang H 
    • Acharya C 
    • An G 
    • et al.
    SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide.
    Leukemia. 2016; 30399-408
  11. 11.
    • Deckert J 
    • Wetzel MC 
    • Bartle LM 
    • et al.
    SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies.
    Clin Cancer Res. 2014; 204574-4583
  12. 12.
    • Attal M 
    • Richardson PG 
    • Rajkumar SV 
    • et al.
    Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
    Lancet. 2019; 3942096-2107
  13. 13.
    • Richardson PG 
    • Attal M 
    • Campana F 
    • et al.
    Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA phase III study design.
    Future Oncol. 2018; 141035-1047
  14. 14.
    • European Medicines Agency
  15. 15.
    Sarclisa (isatuximab-irfc).
     Sanofi-AventisBridgewater, NJ2021
  16. 16.
    • Moreau P 
    • Dimopoulos MA 
    • Mikhael J 
    • et al.
    Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.
    Lancet. 2021; 3972361-2371
  17. 17.
    • Kumar S 
    • Paiva B 
    • Anderson KC 
    • et al.
    International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.
    Lancet Oncol. 2016; 17e328-e346
  18. 18.
    • Miguel JS 
    • Weisel K 
    • Moreau P 
    • et al.
    Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
    Lancet Oncol. 2013; 141055-1066
  19. 19.
    • Dimopoulos MA 
    • Palumbo A 
    • Corradini P 
    • et al.
    Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma.
    Blood. 2016; 128497-503
  20. 20.
    • Oronsky B 
    • Carter CA 
    • Reid TR 
    • et al.
    Confirmatory trials in the evaluation of anticancer medicinal products in man—PFS2: a measure of therapeutic action-at-a-distance.
    Neoplasia. 2015; 17716-722
  21. 21.
    • Mikhael J 
    • Belhadj-Merzoug K 
    • Hulin C 
    • et al.
    A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab.
    Blood Cancer J. 2021; 1189
  22. 22.
    • Musto P 
    • Anderson KC 
    • Attal M 
    • et al.
    Second primary malignancies in multiple myeloma: an overview and IMWG consensus.
    Ann Oncol. 2017; 28228-245
  23. 23.
    • Dimopoulos MA 
    • Terpos E 
    • Boccax 
    • et al.
    Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.
    Lancet Oncol. 2021; 22801-812

Plaats een reactie ...

Reageer op "Isatuximab naast pomalidomide + dexamethason geeft betere overall overleving (Mediaan + 6,9 maanden) dan alleen pomalidomide + dexamethason bij patienten met multiple myeoloma (Kahler - botkanker) die zwaar voorbehandeld waren"

Gerelateerde artikelen